All the Active Ingredient Drugs
Carbapenem. Meropenem (as Trihydrate) 500 mg, 1 g. VIAL: 10 X 500 mg, 1 g. Adult.: The dosage and durat. of ther. shall be establish. depend. on type and sever. of infec. and the condit. of the pt.
The recomm. dly. dosage is as follow.:
500 mg IV every 8 hrs. in the tmt. of pneumon., UTI, gynaecolog. infect. such as endometritis, pelvic inflamm. dis., skin and skin structure infect.
1 g IV every 8 hrs. in the tmt. of nosocom. pneumonias, peritonitis, presumed infect. in neutropenic pts., septicaemia.
In CF, doses up to 2 g every 8 hrs. have been used; most pts. have been treated with 2 g every 8 hrs.
In meningitis the recomm. dosage is 2 g every 8 hrs.
When treat. infect. known or suspect. to be caused by Pseudomonas a., a dose of at least 1g every 8 hrs. in adults (max. approved dose is 6g dly. given in 3 divided doses) and a dose of at least 20 mg/kg every 8 hrs. in child. (max. approved dose is 120 mg/kg/dly. given in 3 divided doses) are recomm.
Regular sensitive. testing is recomm. when treat. Pseudomonas a. infec.
There are limited safety data available to support the admin. of a 2g bolus dose in adult. as an IV bolus inject.
Tmt., in adults and child., of the follow. infec. caused by single or multiple bacteria sensit. to meropenem.: Pneumon., Nosocomial Pneumon.; Pulmon. infec. in pts. with CF; UTI; Intra abdom. Infec.; Gynaecolog. Infect., such as endometritis and pelvic inflamm. dis.; Skin & Skin Structure Infect.; Meningit.; Septicaem.
Meronem has proved efficac. alone or in comb. with other antimicrob. agents in the tmt. of polymicrob. infect. There is no experience in paediatr. pts. with neutropen. or primary or second. immunodeficiency.
C/I: Hypersens. Hypersens. to any other carbapenem antibact. agent. Severe hypersens. (e.g. anaphylactic. reaction, severe skin react.) to any other type of beta-lactam antibact. agent (e.g. penicillins /cephalosporins).
Carbapenem. Meropenem 500, 1000 mg. VIAL. pwder for sol. for inj/inf. 1/10 X 500/1000 mg
Adlts: 500 mg IV every 8 hs. in the tmt of pneumonia, UTI, gynaecological infect. such as endometritis, pelvic inflammatory dis., skin and skin structure infect. 1000 mg IV every 8 hs. in the tmt of nosocomial pneumonias, peritonitis, presumed infect. in neutropenic pts, septicaemia.
In CF, doses up to 2 g every 8 hs. have been used.
In meningitis recommen. dosage is 2 g every 8 hs.
When treating infect. known or suspect. to be caused by Pseudomonas aeruginosa, a dose of at least 1g every 8 hs in adlts (max approved dose is 6g/d in 3 div. doses) and at least 20mg/kg every 8 hs in child (max approved dose is 120mg/kg/d in 3 div. doses) are recommen.
Childr. over 3 months and up to 12 years, recomm. dose is 10 to 20 mg/kg every 8 hs. depend. on type and sev. of infect., susceptibility of the pathogen and the condition of the ptt. In childr over 50 kg, adlt dosage should be used. In meningitis and CF, recomm. dose is 40 mg/kg every 8 hs.
Tmt. in adlts and childr of the following sev. infect. caused by sgle or multiple susceptible bacteria sensitive to Meropenem: - Pneumonias and nosocomial pneumonias. - Pulmonary infect. in patients with CF. - UTI. - Intra-abdominal infect. - Gynecological infect. such as endometritis and pelvic inflamm. dis. - Skin and skin struct. infect. - Meningitis. - Septicemia. This drug has proved efficacious alone or in combin. with other antimicrobial agents in the tmt. of polymicrobial infect. There is no experience in ped. pts with neutropenia or prim. or second. immunodef.
C/I: Hypersens. incl. to any other carbapenem antibacterial agent. Sev. hypersens, (e.g. anaphylactic reaction, sev. skin reaction) to any other type of betalactam (e.g. penicillins or cephalosporins).
